Literature DB >> 17147493

A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects.

Timothy W Tobery1, Sheri A Dubey, Kiersten Anderson, Daniel C Freed, Kara S Cox, Jing Lin, Michael T Prokop, Kara J Sykes, Robin Mogg, Devan V Mehrotra, Tong-Ming Fu, Danilo R Casimiro, John W Shiver.   

Abstract

Currently, there are numerous candidate HIV vaccines aimed at inducing T-cell mediated immune responses against HIV. To assess the immunogenicity of such vaccines, a reliable T cell assay must be utilized and typically one of the following assays is chosen for this purpose: bulk culture CTL, MHC I tetramer staining, IFN-gamma ELISPOT, or IFN-gamma intracellular cytokine staining. In this paper we report a comparison of the T cell responses detected by each assay in a large cohort of healthy normal volunteers vaccinated with adenovirus serotype 5 expressing HIV gag. Using stringently validated formats of each of these assays and pools of overlapping HIV gag peptides, we demonstrate that there is a high degree of correlation between all four of the common T cell assays, but inherent differences in the sensitivity of each assay to detect responders. In this study, the ELISPOT assay is shown to have the greatest sensitivity in detecting vaccine responses, while the ICS assay, although less sensitive, has the advantage of providing additional information on the phenotype of the responding cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17147493     DOI: 10.1089/aid.2006.22.1081

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  18 in total

1.  Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study.

Authors:  Jonathan Z Li; Andrea Heisey; Hayat Ahmed; Hongying Wang; Lu Zheng; Mary Carrington; Terri Wrin; Robert T Schooley; Michael M Lederman; Daniel R Kuritzkes
Journal:  AIDS       Date:  2014-11-28       Impact factor: 4.177

2.  Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.

Authors:  Glenda E Gray; Mary Allen; Zoe Moodie; Gavin Churchyard; Linda-Gail Bekker; Maphoshane Nchabeleng; Koleka Mlisana; Barbara Metch; Guy de Bruyn; Mary H Latka; Surita Roux; Matsontso Mathebula; Nivashnee Naicker; Constance Ducar; Donald K Carter; Adrien Puren; Niles Eaton; M Julie McElrath; Michael Robertson; Lawrence Corey; James G Kublin
Journal:  Lancet Infect Dis       Date:  2011-05-11       Impact factor: 25.071

3.  Quality monitoring of HIV-1-infected and uninfected peripheral blood mononuclear cell samples in a resource-limited setting.

Authors:  Robert E Olemukan; Leigh Anne Eller; Benson J Ouma; Ben Etonu; Simon Erima; Prossy Naluyima; Denis Kyabaggu; Josephine H Cox; Johan K Sandberg; Fred Wabwire-Mangen; Nelson L Michael; Merlin L Robb; Mark S de Souza; Michael A Eller
Journal:  Clin Vaccine Immunol       Date:  2010-03-03

4.  Molecular determinants of T cell epitope recognition to the common Timothy grass allergen.

Authors:  Carla Oseroff; John Sidney; Maya F Kotturi; Ravi Kolla; Rafeul Alam; David H Broide; Stephen I Wasserman; Daniela Weiskopf; Denise M McKinney; Jo L Chung; Arnd Petersen; Howard Grey; Bjoern Peters; Alessandro Sette
Journal:  J Immunol       Date:  2010-06-16       Impact factor: 5.422

5.  Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.

Authors:  Jonathan Z Li; Zabrina L Brumme; Chanson J Brumme; Hongying Wang; John Spritzler; Michael N Robertson; Michael M Lederman; Mary Carrington; Bruce D Walker; Robert T Schooley; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

6.  AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.

Authors:  Robert T Schooley; John Spritzler; Hongying Wang; Michael M Lederman; Diane Havlir; Daniel R Kuritzkes; Richard Pollard; Cathy Battaglia; Michael Robertson; Devan Mehrotra; Danilo Casimiro; Kara Cox; Barbara Schock
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

7.  Multiple T-cell responses to human immunodeficiency virus type 1 are enhanced by dendritic cells.

Authors:  Xiao-Li Huang; Zheng Fan; Luann Borowski; Charles R Rinaldo
Journal:  Clin Vaccine Immunol       Date:  2009-08-19

8.  Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.

Authors:  Mark J Boaz; Peter Hayes; Tony Tarragona; Laura Seamons; Andrew Cooper; Josephine Birungi; Paul Kitandwe; Aloysius Semaganda; Pontiano Kaleebu; Gwynneth Stevens; Omu Anzala; Bashir Farah; Simon Ogola; Jackton Indangasi; Patrick Mhlanga; Melanie Van Eeden; Madhuri Thakar; Ashwini Pujari; Shadri Mishra; Nilu Goonetilleke; Stephen Moore; Abdul Mahmoud; Pattabiraman Sathyamoorthy; Jayashri Mahalingam; Paranji R Narayanan; Vadakkuppattu D Ramanathan; Josephine H Cox; Len Dally; Dilbinder K Gill; Jill Gilmour
Journal:  Clin Vaccine Immunol       Date:  2008-12-17

9.  Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity.

Authors:  Lingshu Wang; Cheng Cheng; Sung-Youl Ko; Wing-Pui Kong; Masaru Kanekiyo; David Einfeld; Richard M Schwartz; C Richter King; Jason G D Gall; Gary J Nabel
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

10.  HV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmission.

Authors:  Grace C John-Stewart; Dorothy Mbori-Ngacha; Barbara Lohman Payne; Carey Farquhar; Barbra A Richardson; Sandra Emery; Phelgona Otieno; Elizabeth Obimbo; Tao Dong; Jennifer Slyker; Ruth Nduati; Julie Overbaugh; Sarah Rowland-Jones
Journal:  J Infect Dis       Date:  2009-03-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.